placeholder

RezūmTM
Water Vapour Therapy

Durable relief for your patients

Which is the data behind Water Vapour Therapy with Rezūm?

Rezūm Water Vapour Therapy is a thermal therapy, which uses convective water vapour to ablate excess prostate tissue in men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).1

It is a minimally invasive option for men who may not want to rely on pharmaceutical management of their symptoms. This advanced technology can enable you to achieve significant clinical improvements and a lasting response for your patients.1,2

How does it works?

Rezūm Water Vapour Therapy can deliver benefits in three key areas:

Long-term Durability

Rezūm uses convective energy to remove obstructive prostate tissue with a surgical retreatment rate of only 4.4% at 5 years

Surgical retreatment rate after Rezūm treatment
rezum treatment
Sustained Symptom Relief and QOL Improvement

Compared to baseline

graphics-sustained-symptom-relief-QOL-improvements

Versatile to Treat Median Lobe Obstruction (MLO)

rezum treatment study rate

 

Rezūm can treat lateral and central zones without physicians having to learn an advanced of men in study technique

Positive Safety Profile and Preserves Sexual Function

checkmark-on-shield

 

No late occurring adverse events or de novo erectile dysfunction reported at 5 years

Which is the potential value for your treatment centre?

 

Not only does Rezūm possess a minimal learning curve for physicians,1 it can also deliver value to your centre through its short procedural time and length of stay.1,8 In some countries cost modelling estimates that Rezūm is cost saving compared with standard treatments.12 Identification of treatments for LUTS/BPH that demonstrate cost-effectiveness is paramount** as reimbursement for patient care moves from volume-based services to value-based services.9

 

With its durable clinical benefits 1, short procedural time and short length of stay1,8 Rezūm may lead to cost savings 10,11 as well as capacity impact reduction vs standard of care*.11

How can we help you?

 

1. McVary KT, Rogers T, Roehrborn CG. Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. Urology. 2019;126:171–17
2.McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2021:206(3):715–724.*
3. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of Rezūm water vapor thermal therapy for treatment ofmoderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021 Apr 19. Online ahead of print.
4. Rezum II Trial – BSC data on file.
5. McVary KT, Roehrborn CG. Three-Year Outcomes of the Prospective, Randomized Controlled Rezūm™ System Study: Convective Radiofrequency Thermal Therapy for Treatmentof Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Urology. Elsevier Inc.; 2018;111: 1–9. doi:10.1016/j.urology.2017.10.023.
6. McVary KT, Rogers T, Roehrborn CG. Rezūm™ Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year ResultsFrom Randomized Controlled Study. Urology. Elsevier Inc.; 2019;126: 171–179. doi:10.1016/j.urology.2018.12.041.
7. McVary KT, Roehrborn C. Five year results of the prospective, arndomized, controlled trial of water thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.J Urol. 2020;203: e1021
8. Westwood J, Geraghty R, Jones P, et al. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Ther Adv Urol. 10(11):327–333.
9. Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clinicoecon Outcomes Res. 2017;10:29–43.
10. NICE Guidance on Rezum https://www.nice.org.uk/guidance/mtg49/chapter/1-Recommendations
11. Rob S Blissett, Deirdre B Blissett, Martina Oselin, et al. Transurethral water vapor therapy for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a cost-minimization and budget impact analysis from an Italian healthcare perspective, Minerva Urol Nephrol. 2022 Dec 23.
12. Alberto De la Cuadra-Grande, Jorge Rioja-Zuazu,Mario Domínguez-Esteban, et al., Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system, Expert Rev Pharmacoecon Outcomes Res. 2023 Mar 20;1-12.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.